mass

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

...he natural disease, a vaccine would not be used in mass populationimmunization programs unless they were actually used or asignificant threat. In that event, the vaccine would have to bemade available for widespread dissemination for rapid andconvenient vaccination of a large population. The only vaccinea...

Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics

...renewing injured cells. They are also found in the mass of normalcells that mix with cancer cells to make up a solid tumor.Researchers believe mesenchymal stem cells “see” atumor as a damaged organ and migrate to it, and so might beutilized as a “vehicle” for treatment that can fin...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

...he natural disease, a vaccine would not be used in mass populationimmunization programs unless they were actually used or asignificant threat. In that event, the vaccine would have to bemade available for widespread dissemination for rapid andconvenient vaccination of a large population. The only vaccinea...

A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

....(TM) resulted in a sustained increase inbeta cell mass and function. These clinical improvements, includingHbA1c reductions greater than 1% in patients six monthpost-treatment, highlight the potential that E1-I.N.T.(TM) therapycould provide patients significant clinical benefit in excess of 6months. Saf...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

...LSFRS-R,vital capacity, total body weight and body mass index (a measure ofobesity). In the absence of placebo control, CytRx chose to comparethe open-label clinical trial results with the placebo group of arecently-published clinical trial (Cudkowicz, M.E., et. al., Annalsof Neurology 2006 volume 60:22-3...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

... stemcells, which may lead to a reduction of tumor mass by these drugsalone or by combining them with standard therapies." References 1 Dalerba P, Dylla SJ, Park I-K et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104:10158-63 ...

ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model

...gent for the treatment of bone loss, preservedbone mass and architecture in a murine model of multiple myeloma.Multiple myeloma is a malignancy of plasma cells in the bone marrowthat disrupts normal bone marrow function resulting in fractures,vertebral compressions and bone pain. The data were presented t...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

... dosage adjustment is necessary based on BMI. Body mass indexhad no clinically meaningful effect on the pharmacokinetics ofsitagliptin based on a composite analysis of Phase I pharmacokineticdata and on a population pharmacokinetic analysis of Phase I and PhaseII data. Gender No dosage adjustment is...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

... dosage adjustment is necessary based on BMI. Body mass indexhad no clinically meaningful effect on the pharmacokinetics ofsitagliptin based on a composite analysis of Phase I pharmacokineticdata and on a population pharmacokinetic analysis of Phase I and PhaseII data. Gender No dosage adjustment is...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...ith lapatinib) showed 10% reduction in tumor mass (change consistent with tumor necrosis) and a decrease in 2 tumor markers (64% CEA, 63% CA27); this patient continues on study; -- 5 patients had extended stable disease (4, 5, 6+, 11+ and 12 months). Of the 3 patients with ovarian ...

GTx Announces Presentation of Ostarine and Acapodene Data at 2007 ASCO Annual Meeting

...tingthe effects of Ostarine treatment on lean body mass and functionalperformance in 120 elderly males and...opausal females. -- "Ostarine increases lean body mass and improves physicalperformance in healthy elderly subjects: Implications for cancercachexia patien...

New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia

...ients experienced decreases in body weight andbody mass index vs. placebo over six months. * Bifeprunox patients showed favorable effects on totalcholesterol, triglycerides, very low-density lipoprotein andlow-density lipoprotein, comparable with placebo over a six-monthperiod. In these analyses, the mo...

Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

...rkets for bothtravelers in developed countries and mass immunization programs indeveloping countries." The Phase 1/2 study was an in-patient dose-escalating clinicaltrial aimed at determining the safety and immunogenicity of thesingle-dose, oral Ty800 vaccine. The trial evaluated threeescalating dose lev...

Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in Preclinical Studies

...ts negative regulators of muscle toincrease muscle mass and strength as a potential treatment forneuromusc... myostatin has been shown tocause a loss in muscle mass and strength, and inhibition ofmyostatin results in the selective increase in skeletal muscle massan...

Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies

...ated the ability of the compound to increasemuscle mass and strength in normal mice and in murine models o...ts negative regulators of muscleto increase muscle mass and strength as a potential treatment forneuromuscular diseases and cancer-related muscle loss. The ...

Study Supports Cost-Effectiveness of Medtronic's Spasticity Treatment for Children with Cerebral Palsy

...pumpalarms. Children should be of sufficient body mass to accommodate thepump. The safety and efficacy of ITB Therapy in pediatric patientsbelow the age of four have not been established. More information about ITB Therapy is available online atwww.spasticity.com or by calling toll-free 1-800-856-3823. ...

Ferring Reports on ENDOMETRIN Presentations at Pacific Coast Reproductive Society Annual Meeting

...ed basal folliclestimulating hormone (FSH) or body mass index (BMI). Excellentcontinuing pregnancy rates were observed across a broad range ofpatient types with the use of BRAVELLE, MENOPUR and ENDOMETRIN. Once-Daily Mixed Protocol The trial data also demonstrated that administration of MENOPURand BRAVE...

New Data Confirm That Use of Levemir Can Limit Weight Gain

...ir® was shown to increase with increasing body mass index(BMI).(11) Thus, the weight advantage of Levemir® tended to bemore pronounced in more overweight patients. For further information please contact Michael Laub Tel: (+45) 4442 1960 About Levemir® Levemir® is a long-actin...

Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo

...atients experienced decreases in body weight, body mass index (BMI) and prolactin and had an extrapyramidal side effects profile similar to placebo. -- Weight, BMI and lipids were assessed in patients with acute exacerbations of schizophrenia in an analysis of another Phase 3, ...

ACC Presentation Indicates Interleukin-1 Gene Variants Determine Increased Risk for Coronary Artery Disease from Oxidized Phospholipids

...stat(R) through the nation'slargest food, drug and mass retailers. The Company's currentdevelopment programs focus on osteoporosis and weight managementgenetic risk assessment tests, as well as its new proprietaryOTCeuticals for distribution through Alan James Group. The Companyexpects that these programs...

Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice

...uch asbreathing. The cancer most often occurs as a mass or lump on theadrenal glands, which are located on top of the kidneys. While chemotherapy and radiation therapy are generally effectivefor some cases of the disease, the prognosis is poor for childrenwith high-risk neuroblastoma. “Neuroblast...

Framingham Study Shows Parents Who Live Long Pass On Lower Risk of Cardiovascular Disease

...tte smoking, blood pressure, cholesterol, and body mass index(BMI). In addition, they compared the offsprings' Framingham RiskScores, a summary score based on the combined contribution oftraditional cardiovascular risk factors. In general, the group in which both parents survived to age 85had significant...

Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients

...edas stable disease had an overall decrease tumour mass with anassociated decrease of greater than 50% in CA-125 after 9 doses ofCTCE-9908 while receiving no other therapy. CA-125 is an ovariancancer biomarker that is used to monitor disease status andresponse to treatment. The daily infusions at all dos...

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

...ed chemotherapeuticdrugs. Also being presented are mass tissue sample screening data,which show that L-DOS47 binds not only to primary lungadenocarcinoma tissues preferentially over a host of othercancerous or normal tissues, but also to metastasized cells inlymph nodes. The poster also highlights the abi...